title: Review of Azithromycin Ophthalmic 1% Solution (AzaSite(®)) for the Treatment of Ocular Infections.
abstract: AzaSite(®) (azithromomycin 1.0%) ophthalmic solution was approved in 2007 by the US Food and Drug Administration (FDA) as the first commercially available formulation of ophthalmic azithromycin for the treatment of bacterial conjunctivitis. AzaSite(®) utilizes a vehicle delivery system called DuraSite(®), which stabilizes and sustains the release of azithromycin to the ocular surface, leading to a longer drug residence time, less frequent dosing, and an increase in patient compliance. AzaSite(®) is a broad spectrum antibiotic, effective against Gram-positive, Gram-negative, and atypical bacteria. AzaSite(®) has been studied for the treatment of ocular conditions beyond its clinical indication. A number of clinical studies have evaluated its efficacy and safety in the management of ocular conditions such as bacterial conjunctivitis and blepharitis on both the pediatric and adult populations. This article aims to evaluate the peer-reviewed published literature on the use of azithromycin 1.0% ophthalmic for current and possible future ophthalmic uses.
authors: Illinois College of Optometry, Department of Clinical Education, 3241 South Michigan Avenue, Chicago, Illinois 60616, USA.
authors: Dominick L
authors: DL
authors: Opitz
authors: Jennifer S
authors: JS
authors: Harthan
keywords: AzaSite®; DuraSite®; azithromycin; bacterial conjunctivitis; blepharitis
references: J Ocul Pharmacol Ther. 2009 Oct;25(5):433-9
references: 19857105
references: PLoS Negl Trop Dis. 2010 Nov 23;4(11):e895
references: 21124889
references: Clin Ophthalmol. 2007 Dec;1(4):519-25
references: 19668531
references: Br J Ophthalmol. 2007 May;91(5):667-72
references: 17005549
references: Community Eye Health. 1999;12(32):55-6
references: 17492006
references: Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5623-9
references: 20538995
references: Clin Ophthalmol. 2008 Mar;2(1):241-2
references: 19668414
references: Adv Ther. 2008 Sep;25(9):858-70
references: 18781287
references: Pediatr Res. 2007 Oct;62(4):483-8
references: 17667842
references: Clin Ophthalmol. 2011;5:801-9
references: 21750614
references: J Cataract Refract Surg. 2012 Jan;38(1):137-45
references: 22078120
references: Clin Infect Dis. 1998 Jul;27(1):28-32
references: 9675445
references: Curr Pharm Des. 2004;10(25):3045-53
references: 15544496
references: DNA Cell Biol. 2002 May-Jun;21(5-6):415-20
references: 12167244
references: Adv Ther. 2008 Mar;25(3):208-17
references: 18369536
references: Am J Ophthalmol. 2010 Oct;150(4):498-504.e1
references: 20678751
references: Eur J Ophthalmol. 2008 Jan-Feb;18(1):13-20
references: 18203079
references: J Ocul Pharmacol Ther. 2009 Apr;25(2):133-9
references: 19284320
references: Ocul Surf. 2009 Apr;7(2 Suppl):S1-S14
references: 19383269
references: Eye Contact Lens. 2012 Mar;38(2):73-9
references: 22157392
references: Clin Ophthalmol. 2007 Jun;1(2):177-82
references: 19668507
references: Br J Gen Pract. 2001 Jun;51(467):473-7
references: 11407054
references: Curr Med Res Opin. 2011 Jan;27(1):171-8
references: 21138337
references: Ann Ophthalmol (Skokie). 2008 Summer;40(2):68-74
references: 19013912
references: Antimicrob Agents Chemother. 1990 Jun;34(6):1056-60
references: 2168141
references: Cornea. 2010 Jul;29(7):781-8
references: 20489573
references: Eur J Ophthalmol. 2008 Nov-Dec;18(6):858-68
references: 18988154
references: Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3425-9
references: 17652708
references: N Engl J Med. 2004 Nov 4;351(19):1962-71
references: 15525721
references: Ophthalmic Res. 1999;31(1):47-52
references: 9831822
references: Ann Pharmacother. 1998 Jul-Aug;32(7-8):785-93
references: 9681095
references: Am J Ophthalmol. 2010 Nov;150(5):744-751.e2
references: 20813346
references: Antimicrob Agents Chemother. 1987 Dec;31(12):1939-47
references: 2449865
references: Clin Ther. 2008 Nov;30(11):2005-14
references: 19108788
references: J Ocul Pharmacol Ther. 2010 Dec;26(6):557-62
references: 21029017
references: Arch Ophthalmol. 1998 Dec;116(12):1625-8
references: 9869792
references: J Antimicrob Chemother. 1998 Mar;41 Suppl B:47-50
references: 9579712
references: Eur J Ophthalmol. 2010 Nov-Dec;20(6):979-88
references: 20544676
references: J Pharmacol Exp Ther. 2000 Jan;292(1):156-63
references: 10604943
references: Invest Ophthalmol Vis Sci. 2011 Apr 19;52(5):2525-31
references: 21296809
references: Eye (Lond). 1995;9 ( Pt 1):102-9
references: 7713236
references: Clin Ophthalmol. 2007 Mar;1(1):3-10
references: 19668461
references: Antimicrob Agents Chemother. 1989 Mar;33(3):277-82
references: 2543276
references: Cornea. 2010 Aug;29(8):871-7
references: 20508503
references: Pediatr Infect Dis J. 2010 Mar;29(3):222-6
references: 19935122
references: Am J Infect Control. 2008 Dec;36(10):S175.e9-11
references: 19084156
references: J Ocul Pharmacol. 1994 Winter;10(4):633-41
references: 7714407
references: Am J Ophthalmol. 2008 Jun;145(6):959-65
references: 18374301
references: Clin Exp Optom. 2011 Mar;94(2):200-6
references: 21083761
references: Int J Pharm. 2002 Jul 8;241(1):135-43
references: 12086729